两剂量赛尼哌在预防移植肾急性排斥反应中的临床效果

Two Doses Regimen of Zenapax in the Prevention of Acute Renal Allograft Rejection

目的探讨赛尼哌在预防同种肾异体移植术后急性排斥反应（AR）的作用，并评估其安全性。方法44例肾移植患者随机分为赛尼哌治疗组22例与对照组22例，冶疗组在术前及术后14d分别静滴赛尼哌一个剂量，对照组以生理盐水为安慰剂，观察期为6个月。结果赛尼哌组在3个月内急性排斥反应发生率显著低于对照组（P〈0．05），在感染及副作用方面与对照组无显著性差异，随访期内，人肾均存活。结论赛尼哌是一种强效安全的免疫抑制剂，可显著降低移植肾AR的发生率。

Objective To investigate the use of zenapax in the prevention of acute rejection （AR） in renal transplant recipients. Methotis 44 patients were randomly divided into two groups, i.e. treatment group （ n = 22） and control group （ n = 22）. One doses zenapax was given within 24 h before pretransplantation and 14 days after transplantation separately. Observation period lasted for 6 months. Results Acute rejection rate was lower in the zenapax group as compared to tire control group within 6 months, No differences occurred between zenapax group and control group in infection and adverse events, Both patient and graft were survival in follow up time. Conclusion Zenapax is a safe and effective induction therapy in sensitized recipients, and could prevent AR in renal transplantation recipients.